Literature DB >> 7648711

The association of complement activation at a low temperature with hepatitis C virus infection in comparison with cryoglobulin.

K Ueda1, H Nakajima, T Nakagawa, A Shimizu.   

Abstract

Complement activation at a low temperature in vitro and cryoglobulinaemia are associated with hepatitis C virus (HCV) infection. The frequency of HCV antibody positivity determined in serum specimens that showed the cold-dependent activation of complement was 100%, whereas it was 48% among sera with cryoglobulin. On the other hand, the frequency of cold activation among HCV-infected sera was 41%, and that of cryoglobulin 48%. Cold activation was not found in any HCV- sera studied, whereas cryoglobulin was found at a frequency of 14% in HCV- sera. Cold activation was also absent among hepatitis B virus (HBV) S antigen or antibody-positive sera, except a few that were both HBV+ and HCV+. Rheumatoid factor was also frequently detected in sera with cold activation or cryoglobulin. Cold activation and cryoglobulin may be generated by common mechanisms in which a low avidity, low temperature-preferring antibody may function. In sera with cold activation, fine particles of immune complexes, which do not form precipitates, may activate the complement system. HCV is a unique virus that coexists with antibody in the serum, therefore the avidity of the antibody for the virus antigen may be low, and occasionally react only at a low temperature. This may be why the in vitro phenomenon related to immune complexes occurs specifically in HCV-infected sera.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648711      PMCID: PMC1553261          DOI: 10.1111/j.1365-2249.1995.tb08352.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Presence of lower temperature-dependent antibody with low avidity to C100-3 (HCV) antigen in voluntary blood donors.

Authors:  M Yamaki; T Shimada; C Matsumoto; J Watanabe; K Nishioka
Journal:  Jpn J Med Sci Biol       Date:  1992-02

2.  Hepatitis C virus in patients with cryoglobulinemia type II.

Authors:  M Pascual; L Perrin; E Giostra; J A Schifferli
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

3.  Cryoglobulinaemia and hepatitis C virus.

Authors:  M Casato; G Taliani; L P Pucillo; F Goffredo; B Laganà; L Bonomo
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

4.  Cutaneous vasculitis and cryoglobulinaemia type II associated with hepatitis C virus infection.

Authors:  J M Durand; P Lefevre; J R Harle; J Boucrat; L Vitviski; J Soubeyrand
Journal:  Lancet       Date:  1991-02-23       Impact factor: 79.321

5.  Antibodies against hepatitis C virus in mixed cryoglobulinemia patients.

Authors:  C Ferri; F Greco; G Longombardo; P Palla; A Moretti; E Marzo; P V Fosella; G Pasero; S Bombardieri
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

6.  Differences between plasma and serum complement in patients with chronic liver disease.

Authors:  S Inai; H Kitamura; T Fujita; J Kojima; K Nagaki
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

7.  Cold activation of complement i. presence of coagulation-related activator.

Authors:  M Kondo; K Hosokawa; M Masuda
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

8.  The reaction of monomeric and aggregated immunoglobulins with C1.

Authors:  W Augener; H M Grey; N R Cooper; H J Müller-Eberhard
Journal:  Immunochemistry       Date:  1971-11

9.  Anticomplementary effect of cryoglobulinemic sera and isolated cryoglobulins.

Authors:  V Balázs; M M Fröhlich
Journal:  Am J Med Sci       Date:  1966-01       Impact factor: 2.378

10.  The cold activation of the classical complement pathway: The cause of the differences between plasma and serum complement in liver cirrhosis.

Authors:  H Kitamura; K Nagaki; K Inoshita; K Iida; S Inai
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

View more
  1 in total

1.  Complement C4 monitoring in the follow-up of chronic hepatitis C treatment.

Authors:  C Dumestre-Perard; D Ponard; C Drouet; V Leroy; J-P Zarski; N Dutertre; M G Colomb
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.